Get started
Author

Eduardo Martínez-Díaz

Observed names: E. Martínez-Díaz, Eduardo Martinez-Diaz
ORCID: 0000-0001-8030-2364
Observed ORCID: 0000-0001-8030-2364
OpenAlex ID: A5074644859
An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen
2022 · Miladys Limonta-Fernández, Glay Chinea-Santiago, et al. · New Biotechnology · 69
Immunogenicity and Safety Assessment of a SARS-CoV-2 Recombinant Spike RBD Protein Vaccine (Abdala) in Paediatric Ages 3 to 18 Years Old: A Double-Blinded, Multicentre, Randomised, Phase 1/2 Clinical Trial (ISMAELILLO Study)
2022 · Zurina Cinza-Estévez, Sonia Resik-Aguirre, et al. · EClinicalMedicine · 11
PDF
Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical Trial
2024 · Gilda Lemos-Pérez, Yinet Barrese-Pérez, et al. · Vaccines · 9
PDF
A narrative review on Epidermal Growth Factor (EGF) intralesional infiltrations for diabetic complex wounds: The rational of an innovative delivery route
2022 · Jorge Berlanga-Acosta, Jose Fernandez-Montequin, et al. · Vascular Diseases and Therapeutics · 2
PDF
Works count: 5
Citation count: 91
H-index: 3
I10-index: 2
Year
Topic
Type